Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 660  

 
   Table of Contents      
CASE REPORT
Year : 2015  |  Volume : 14  |  Issue : 1  |  Page : 51-52

Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma


1 Department of Gastroenterology, School of Medicine, Ankara University, Ankara, Turkey
2 Department of Nuclear Medicine, School of Medicine, Ankara University, Ankara, Turkey

Date of Web Publication2-Feb-2015

Correspondence Address:
Onur Keskin
Department of Gastroenterology, School of Medicine, Ankara University, Ibni Sina Hospital, Ankara
Turkey
Login to access the Email id


DOI: 10.4103/1450-1147.150548

PMID: 25709546

Rights and Permissions
   Abstract 

Palliation of bone metastases in hepatocellular carcinoma (HCC) is sometimes difficult. Systemic pharmaceuticals have been successfully used for the palliation of bone metastasis for many years. Safety of these agents in HCC is not known completely. We presented a male patient with decompensated liver cirrhosis with HCC. Multifocal bone metastases developed in this patient and he had refractory bone pain. We treated this patient with Sm-153 (samarium) after obtaining patient's consent. Two days after treatment, he experienced dyspnea and we detected a massive hemorrhagic pericardial effusion. He died due to this unexpected bleeding. We should use this radiopharmaceutical treatment cautiously in these cytopenic cirrhotic patients.

Keywords: Bone metastasis, hepatocellular carcinoma, Sm-153


How to cite this article:
Keskin O, Soydal C, Deda X, Manti B, Tuzun A. Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma. World J Nucl Med 2015;14:51-2

How to cite this URL:
Keskin O, Soydal C, Deda X, Manti B, Tuzun A. Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma. World J Nucl Med [serial online] 2015 [cited 2019 Dec 15];14:51-2. Available from: http://www.wjnm.org/text.asp?2015/14/1/51/150548


   Introduction Top


Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. The incidence of bone metastasis in HCC is increasing over time. Bone metastasis was found in 13% of the HCC patients in a Japan study. [1] Bone metastasis may cause pain and functional loss in this patient group. Pain palliation is unsuccessful in at least 45% of patients with bone metastasis. [2] Systemic radiopharmaceuticals may be used in the palliation of pain due to multifocal osteoblastic metastasis. One of these radiopharmaceuticals is samarium Sm-153 Lexidronam (Sm-153). Sm-153 is produced by neutron irradiation of Sm-152 oxide and makes a complex with ethylenediaminetetramethylenephosphonic acid (EDTMP) to form Sm-153-EDTMP. In this form, samarium selectively accumulates within metastatic bone tissue. [3] Mild hematological side-effects (mild myelosuppression) have been reported with this agent. In this report, we share our experience in use of Sm-153 EDTMP in a patient with hepatitis B virus (HBV) related decompensated liver cirrhosis.


   Case Report Top


The case we present here is about a 49-year-old male patient who had a history of HBV related chronic liver failure and HCC for 2 years developed multiple osteoblastic bone metastasis [Figure 1] and bone pain was refractory to analgesic treatments (tramadol, fentanyl). SM-153 treatment was planned for palliation of bone pain. He was mildly decompensated in terms of liver disease, and there was no significant finding except minimal pleural effusion and a chronic infiltrative area at chest X-ray graphic examination taken before the procedure [Figure 2]a. Laboratory findings of patient at the day of treatment were Hb: 9.3 g/dl, Plt: 66.000 and white blood cell (WBC): 3400; creatinine 0.6 mg/dl, glomerular filtration rate (GFR): Normal and total bilirubin: 5.09 mg/dl. Sm-153 intravenous (IV) bolus (1 mCi/kg) and 100 cc %0.9 NaCl 1 h IV infusion was applied for pain palliation. Sm-153 accumulation at bone metastatic sites was shown by total body scintigraphic imaging at 24 th h. Patient had dyspnea and the cardiac shadow was more prominent at chest X-ray taken 2 days after the SM-153 treatment [Figure 2]b. Massive pericardial effusion was determined at echocardiography. Bilateral pleural effusion, massive pericardial effusion and subtotal collapse of right lung were noticed at thorax CT [Figure 2]c. Pericardiotomy was performed, and the effusion was hemorrhagic. No malignant cell was determined at cytologic examination, and there was no proliferation in culture of pericardial fluid. Approximately, 500 cc/day pericardial hemorrhagic fluid was drained. The bilirubin level increased up to 30 mg/dl and the patient died 20 days after the application of Sm-153.
Figure 1: Scintigraphic examination of patient

Click here to view
Figure 2: Chest X-ray graph of patient before procedure (a), and after procedure (b), thorax computed tomography examination after Sm-153 treatment (c)

Click here to view



   Discussion Top


Radiopharmaceutical drugs are important alternatives in pain palliation of osteoblastic bone metastases. Although there is no certain approach in this issue, most centers prefer the minimal standards of Hb > 9 g/dl, WBC >3500, neutrophil >1500, Plt >100,000, GFR >50 ml/min. The effectiveness and reliability of Samarium have been studied mostly in prostate and breast cancers until now. [4] However, there is no sufficient data about the use of radiopharmaceutical drugs in HCC. Because HCC mostly origins from underlying cirrhosis and most of the cirrhotic patients are pancytopenic due to hypersplenism, all types of systemic treatment have to be used very carefully. Our patient had critical liver disease and died due to a rapid fulminant progression with pericardial effusion due to an unexpected hemorrhage. Systemic radiopharmaceutical drugs should be used cautiously in these patients.

 
   References Top

1.
Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001;13:1083-8.  Back to cited text no. 1
    
2.
Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906.  Back to cited text no. 2
    
3.
Paes FM, Ernani V, Hosein P, Serafini AN. Radiopharmaceuticals: When and how to use them to treat metastatic bone pain. J Support Oncol 2011;9:197-205.  Back to cited text no. 3
    
4.
Fischer M, Kampen WU. Radionuclide Therapy of Bone Metastases. Breast Care (Basel) 2012;7:100-07.4.  Back to cited text no. 4
    


    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
    References
    Article Figures

 Article Access Statistics
    Viewed1619    
    Printed44    
    Emailed0    
    PDF Downloaded151    
    Comments [Add]    

Recommend this journal